Neopep-S Ingredient Easy Dew MD Regen Cream

NCT05982535 | Completed

• 1 other identifier: G2206
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this clinical study is to provide patients diagnosed with dry skin due to various causes such as atopic dermatitis and Yangjin The effect on skin regeneration after applying EasyDew MD Regen Cream containing Neopep-S, a regeneration factor, and It is intended to assess safety.

Conditions

Dry Skin

Outcome Measures

Primary Outcomes (1)

• Transepidermal water loss

  Percutaneous moisture loss measured

  before and one month after medical device application

Secondary Outcomes (3)

• Investigator Global Assessment Scale

  before medical device application and one month after medical device application

• Dermatology Life Quality Index

  before medical device application and one month after medical device application

• Itching score

  before medical device application and one month after medical device application

Study Arms (2)

Easy Dew MD Regen Cream

EXPERIMENTAL

The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.

Device: Easy Dew MD Regen Cream

Physiogel Stability Intensive Cream MD

ACTIVE COMPARATOR

The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.

Device: Easy Dew MD Regen Cream

Interventions

Easy Dew MD Regen Cream DEVICE

The subject applies the provided medical device twice a day (morning and evening) to areas with symptoms of dry skin so that it can be absorbed well.

Also known as: Physiogel Stability Intensive Cream MD

Easy Dew MD Regen Cream; Physiogel Stability Intensive Cream MD

Eligibility Criteria

• Age: 19 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects diagnosed with xerotic skin among adults aged 19 to 80 years
• Subjects who have voluntarily decided to participate in this clinical study and signed a written informed consent

You may not qualify if:

• Subjects with uncontrolled diabetes
• Immunosuppressants, corticosteroids, cytotoxic drugs, anticoagulants, etc. are included in the results You are on long-term or scheduled to receive medication that may affect you a person who is subject to
• Acute or chronic skin disease; stage in progress or active in the area of application Subject to bacterial or viral infection
• Where the researcher's judgment determines that participation in the study is inappropriate

Sponsors & Collaborators

• Eun-ji Kim: lead

Study Sites (1)

Ajou University Hospital

Gyeonggi-do, South Korea

Location

Study Officials

• Jihye Lee

  CGBio Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Clinical Trial Manager

Study Record Dates

• First Submitted: July 28, 2023
• First Posted: August 8, 2023
• Study Start: November 11, 2022
• Primary Completion: July 27, 2023
• Study Completion: July 27, 2023
• Last Updated: August 8, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)